about
New common variants affecting susceptibility to basal cell carcinomaMelanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometryA large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanomaSentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival.World Health Organization experience in the treatment of melanoma.Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas.Armed antibodies for cancer treatment: a promising tool in a changing era.microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.NFATc2 is an intrinsic regulator of melanoma dedifferentiation.Self-detected cutaneous melanomas in Italian patients.Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma.Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs.Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma PatientsPrediction of survival in patients with thin melanoma: results from a multi-institution study.CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients.The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis.Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.Pediatric patients with cutaneous melanoma: A European study.Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy.Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma.Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience.Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes.Association of promoter polymorphism -765G>C in the PTGS2 gene with malignant melanoma in Italian patients and its correlation to gene expression in dermal fibroblasts.Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.Patterns of Detection of Superficial Spreading and Nodular-Type Melanoma: A Multicenter Italian StudyA phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patientsIsolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanomaDifferences in Clinicopathological Features and Distribution of Risk Factors in Italian Melanoma PatientsProlonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinomaTreatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Distribution of melanoma on breast surface suggests its etiology
P50
Q24615109-2310EF57-1979-4DF4-A8F8-ED5D9D8FCC73Q28215572-3497A368-1E29-4E9A-90E8-A3249C49DDDCQ28386783-16263034-F9C2-4B5A-8873-B8ADC70C23DBQ34571012-62C89169-6EAA-461A-8C50-2C1C7FBDAF25Q35126565-7517F688-FA0E-4E3D-A077-E2C3041152CAQ36791766-9BDC8325-1A9F-4500-9CA4-E149D7B606E5Q38164189-082F009E-54D3-4182-ABCC-736DAB1CDF18Q38260165-F2E00BFD-8F48-4B27-8644-516DB67EC353Q38376771-51FBC86F-570D-4A89-889F-C18E6A6A0EBBQ38834040-53991A00-9D0C-4B8A-AA3D-4CCF884B090CQ40467334-36325B53-39D8-40BB-BDA0-87FAB3124E26Q40587491-05E6C37A-F2FA-4118-A2DB-66A41013D238Q41740586-A3210672-865B-4F59-81CB-4FA4B3EB64D4Q41951116-92CE8282-258B-4FD8-84EF-EBAE6E5A5E5DQ42111608-3BCBD892-701D-4FDD-BE8D-C4D1E624C448Q43703028-4FC288E3-2208-441A-8135-7D54257426F9Q44176540-3E99C6F0-1479-4FBC-A0E6-3D16E42CC0A9Q44857485-A524FCBC-27B1-4739-B67F-5E6FC69C976FQ47621555-8F443FBE-2F8C-4263-BDED-2FA750FC502BQ47717589-DE86C9BB-D21C-4648-8420-4EE8EAF9FC1EQ48208779-1F40436F-073D-4B90-8B6E-B13DDF47DD6BQ48401064-AEB7B434-8516-494E-BF86-16EACB1A5D0DQ49388044-8F743A4D-8E03-4328-8282-2A35CCF5AA2EQ50600144-E7E7CBC1-48C3-46A3-A3B4-AF146A0742C9Q50876968-C95EC344-CD0C-42CB-9699-40BD34DB1DE2Q50934997-35521C67-F6A9-4C06-95BC-04CA9EADFBF7Q51036583-8C25B31C-2021-42F9-9983-BAA9EA910C86Q51141486-3486E5D8-B24B-4BC7-B579-66CA4C8373F5Q51231567-0D416DFB-58CC-4D26-861D-ED212EABB434Q51742048-1639D214-7C52-443E-BDCA-3C164A22AC76Q51839875-47D99FB0-42A6-49F7-8503-3E6AFD1DFD3BQ53233600-FC775094-534C-4F2A-8EB7-BAE86B81BF55Q55032008-1D820C7C-24FD-4CE0-BB9E-1CEA8AFC82BDQ57419753-FBB619A7-FB79-4429-A617-A9CA9265015FQ57570360-24EFD12B-AA1F-495A-98E8-B5520D677EB1Q57911958-DA9BD6D8-8F12-4B5D-973B-43B200C7A3A4Q58885297-4B70E515-46DA-4DED-B3CD-B2F5463E2648Q60637506-EA43137C-7DB0-47F6-9D43-CA8C5C47C0A8Q64930981-F1BB4535-931C-459F-80ED-01B394256420Q73294066-C52C62E0-1831-458C-A267-774C55951471
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Maurichi
@ast
Andrea Maurichi
@en
Andrea Maurichi
@es
Andrea Maurichi
@nl
Andrea Maurichi
@sl
type
label
Andrea Maurichi
@ast
Andrea Maurichi
@en
Andrea Maurichi
@es
Andrea Maurichi
@nl
Andrea Maurichi
@sl
prefLabel
Andrea Maurichi
@ast
Andrea Maurichi
@en
Andrea Maurichi
@es
Andrea Maurichi
@nl
Andrea Maurichi
@sl
P106
P1153
6602439533
P31
P496
0000-0002-6503-5373